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Background:  Cryotherapy  is  effective  for common  warts,  but for  plantar  warts  available  treatments  often
fail.
Objectives:  Within  a  pragmatic  randomised  controlled  trial, we  examined  whether  subgroups  of common
and  plantar  warts  have  a favourable  natural  course  or response  to treatment  based  on wart-associated
HPV  type.
Study  design:  Consecutive  patients  with  new  common  or plantar  warts  were  recruited  in  30  Dutch  family
practices.  Patients  (n  =  250)  were  randomly  allocated  to liquid-nitrogen  cryotherapy,  40% salicylic  acid
self-application,  or wait-and-see  policy.  Before  treatment,  swabs  were  taken  from  all  separate  warts
and analysed  by  a broad spectrum  HPV  genotyping  assay.  At 13 weeks,  cure  rates  with  95%  conﬁdence
intervals  of  common  and plantar  warts  on  intention  to  treat  basis  were  compared  between  treatment
arms  for  the  different  wart-associated  HPV  types.
Results: In  total, 7% of  swabs  tested  negative  for HPV  DNA  and  16%  contained  multiple  types, leaving  278
of  371  common  swabs  (75%)  and  299 of 373  plantar  swabs  (80%)  with  a single  type  for  analysis.  After
wait-and-see  policy,  cure  rates  were  2/70  (3%,  95%  conﬁdence  interval  1–10)  for HPV  2/27/57-associated
common  warts,  4/58  (7%,  3–16)  for HPV  2/27/57-associated  plantar  warts,  and  21/36 (58%, 42–73)  for
HPV  1-associated  plantar  warts.  After cryotherapy,  cure  rates  were  30/44  (68%,  53–80), 6/56  (11%,  5–21),
and 15/23  (65%,  45–81);  after  salicylic  acid  16/87  (18%,  12–28),  15/60  (25%,  16–37),  and  24/26 (92%,
76–98),  respectively.
Conclusions:  HPV  type inﬂuenced  the  natural  course  and  response  to  treatment  for plantar  warts.  HPV
testing  potentially  optimises  wart  treatment  in  primary  care.. Background
Cutaneous warts are benign papillomas of the skin of which
ommon warts (verrucae vulgaris) and plantar warts (verrucae
lantaris) are most common.1,2 Up to one-third of all pri-
ary schoolchildren have warts, of which two-thirds resolve
Abbreviations: GP, general practitioner; OTC, over-the-counter; HPV, human
apillomavirus; HSL, hyperkeratotic skin lesion; PCR/MPG, polymerase chain reac-
ion/multiplex genotyping; CI, conﬁdence interval.
 Registration of original trial: ISRCTN42730629.
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el.: +31 71 5268444; fax: +31 71 5268259.
E-mail address: s.c.bruggink@lumc.nl (S.C. Bruggink).
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spontaneously within 2 years.3,4 Since warts frequently result in
discomfort,5 2% of the general population and 6% of schoolchildren
present warts to their general practitioner (GP) for treatment,6,7
at a reported cost of £40 million per year in the UK.8 A range
of treatment options are available, 9,10 the most common being
liquid-nitrogen cryotherapy or topical salicylic acid application.11
For common warts cryotherapy showed to be most effective, but
for plantar warts available treatments often fail.12,13 Because of
the benign natural course and limited effectiveness, side-effects
and costs of treatments, some physicians promote a wait-and-see
policy.8,14–16 Deﬁnition of subgroups that will better respond to
Open access under the Elsevier OA license.speciﬁc treatment could improve treatment results, reduce costs,
and limit the burden of side-effects.17
Warts are caused by infection with human papillomavirus
(HPV). More than 120 HPV types, distributed over 5 genera and 16
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pecies, have been described based on their DNA sequences.18,19
evelopment of the HSL-PCR/MPG (hyperkeratotic skin lesion
 polymerase chain reaction/multiplex genotyping) assay has
ecently paved the way for large-scale cutaneous wart-associated
PV typing.20 HPV 2, 27, and 57 from the alpha genus, and HPV
 from the mu  genus are the most prevalent types detected in
utaneous warts.21–27 Since speciﬁc HPV types are related to clin-
cal characteristics such as type of wart (common or plantar) and
ge of the patient, we questioned whether these HPV types could
nﬂuence the natural course or response to treatment.27
. Objectives
Within a randomised controlled trial comparing liquid nitrogen
ryotherapy, topical salicylic acid application, and a wait-and-see
olicy, we examined whether subgroups of common and plantar
arts have a favourable natural course or response to treatment
ased on wart-associated HPV type.
. Study design
This study is a secondary analysis within the WArts Randomized
reatment Study (WARTS, trial registration ISRCTN 42730629). For
etailed information on study design and treatment protocols we
efer to the publication of the original trial.12
.1. Patients and samples
All patients from 4 years of age and older who attended one of
he 30 participating general practices between May  1st 2006 and
anuary 26th 2007 with one or more new cutaneous warts were
ligible. We  deﬁned new cutaneous warts as common or plantar
arts on the skin that were diagnosed in general practice and were
resented for the ﬁrst time without treatment from a physician
r dermatologist in the previous year, regardless of previous self-
reatment with over-the-counter (OTC) medication, and excluded
mmunocompromised patients. Trained research nurses visited the
atients at home to conﬁrm eligibility and collect baseline charac-
eristics, including number, size, location and duration (<6 versus
6 months) of warts.
.2. Randomisation
We  stratiﬁed patients by number of warts (<6 versus ≥6 warts)
nd type of warts (plantar [warts on the soles of the feet] versus
ommon [all other locations, mainly on the hands]). Patients who
ad both plantar and common warts were stratiﬁed according to
here the majority was located. All warts of patients with multiple
arts received the same treatment.
.3. Treatments
We  trained all GPs and assistants in the three 13-week protocols,
hich were designed to reﬂect best practice.10 In the cryotherapy
rotocol, we used a high intensity regimen of one session every 2
eeks until all warts were completely gone. In the salicylic acid
rotocol, salicylic acid 40% in a vaseline album solution was  self-
dministered every day. In the wait-and-see protocol, participants
ere informed about the benign natural course of warts and were
dvised not to undergo treatment for at least 13 weeks..4. Outcome assessment
The trained research nurses assessed wart cure during home
isits at 13 weeks of follow-up, independently of the treatingl Virology 57 (2013) 227– 232
general practice. A wart was considered cured if the wart had visu-
ally disappeared (skin colour and skin lines re-established) and
could no longer be palpated by hand.
3.5. HPV identiﬁcation
At baseline, the nurses took swabs from each single wart by
ﬁrmly rubbing a wetted cotton-tipped stick over the surface of the
wart ﬁve times. This swab technique adequately detects HPV types
compared to wart scab or biopsy.28 We  considered multiple warts
as a cluster when the distance between warts was less than 1 cm.
Only when warts were too close to take separate swabs, a single
swab was taken from the cluster. All swabs were stored in 1 ml  of
saline solution.
To determine HPV type, a broad spectrum PCR–MPG assay was
used for genotyping all known wart-associated HPV types from the
alpha (HPV2, 3, 7, 10, 27, 28, 29, 40, 43, 57, 77, 91 and 94), gamma
(HPV4, 65, 95, 48, 50, 60 and 88), mu (HPV1 and 63) and nu genus
(HPV41). This sensitive and speciﬁc assay (HSL-PCR/MPG assay;
Labo Biomedical Products BV, Rijswijk, The Netherlands) has been
well described and evaluated.20 In short, 10 l of the saline solu-
tion was used in the single-step HSL-PCR, generating a biotinylated
amplimer of 76–84 bp from the L1 region. Subsequently, simulta-
neous identiﬁcation of the 23 HPV genotypes was performed with
bead-based xMAP suspension array technology.
3.6. Statistical analysis
Baseline characteristics of the patients and warts, as well as all
outcomes, were stratiﬁed for common and plantar warts. Because
HPV type is associated with separate warts, we used warts instead
of patients as unit of analysis. The primary outcome measure was
the crude cure rate of separate warts associated with a single HPV
type per treatment arm per speciﬁc wart-associated HPV type at 13
weeks on an intention-to-treat basis. The software package SPSS,
PASW Statistics, release 17.02 was used.
We only compared cure rates for HPV types which had at least
10 warts per treatment arm. To identify subgroups of common
and plantar warts that have a favourable natural course, cure rates
of wait-and-see arms were compared between speciﬁc HPV types
using 95% conﬁdence intervals (CIs). To examine subgroups that
have favourable response to treatment, cure rates of treatment
arms were compared within speciﬁc HPV types using 95% CIs, rel-
ative risks and risk differences.
In addition, per-protocol analysis was performed based on
reported treatment adherence. To explore whether we had created
a speciﬁc subgroup of warts by including only warts with a single
HPV type, we  compared cure rates of warts negative for HPV DNA
and cure rates of warts with multiple HPV types with cure rates of
warts with single HPV type within treatment arms.
4. Results
4.1. Patients and samples
In the original trial, 250 patients with 391 common and 379
plantar warts were included.12 No swabs were available from 20
common and 6 plantar warts (13 warts belonged to four patients
without consent for swabs, and 13 swabs were lost in transport
to the laboratory). A total of 45 common and 4 plantar warts (7%)
swabs tested negative for HPV DNA, and 48 common and 70 plan-
tar warts (16%) contained multiple HPV types per swab, leaving 278
common warts (75%) and 299 plantar warts (80%) with single HPV
type for analysis. A further 6 patients with 7 common and 8 plantar
warts (3%) were lost to follow-up (Fig. 1). Patients were evenly dis-
tributed over treatment arms, but by chance the cryotherapy arm
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Wait and see (n=73)
(84 common; 116 plantar)
Eligible patients (n=250)
(391 common; 379 plantar)
R
Lost to follow-up (n=1)
(0 common; 1 plantar)
Primary analysis at 13 weeks (n=72)
(84 common; 115 plantar)
Cryotherapy (n=71)
(n= 78 common; 90 plantar)
Excluded (n=31):
Missing swabs (20 common; 6 plantar)
HPV DNA negative swabs (45 common; 4 plantar)
Multiple HPV types (48 common; 70 plantar)
Lost to follow-up (n=4)
(7 common; 6 plantar)
Primary analysis at 13 weeks (n=67)
(71 common; 84 plantar)
Salicylic acid (n=75)
(n= 116 common; 93 plantar)
Lost to follow-up (n=1)
(0 common; 1 plantar)
Primary analysis at 13 weeks (n=74)
(116 common; 92 plantar)
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gFig. 1. Flowchart of c
ontained less warts than the salicylic acid and wait-and-see arm
or common warts (p = 0.003) as well as plantar warts (p = 0.069).
Baseline characteristics of patients with complete follow-up
howed that, in the common wart group (n = 103), 54 patients (56%)
ere female, median age was 16 (range 4–73) years, and median
umber of warts was 2 (interquartile range [IQR] 1–4). In the plan-
ar wart group (n = 110), 68 patients (62%) were female, median age
as 11 (range 4–69) years, and median number of warts was also (IQR 1–4). In total, 91 patients had common warts only, 90 had
lantar warts only, and 32 had both common and plantar warts.
The patients had a total of 271 common warts and 291 plantar
arts (Table 1). The common warts were mainly located on hands
able 1
haracteristics of warts associated with a single HPV type (n = 562).
Common warts
(n = 271)
Plantar warts
(n = 291)
Associated HPV typea
HPV 1 20 (7) 85 (29)
HPV 2 80 (30) 35 (12)
HPV 27 65 (24) 71 (24)
HPV 57 56 (21) 68 (23)
Other HPV types 50 (18) 32 (11)b
Location
Sole of the foot – 291 (100)
Dorsum of the foot 26 (10) –
Hand 211 (78) –
Rest of the body 34 (13) –
Wart duration < 6 months 56 (21) 125 (43)
Size of wart in millimetre (median, IQR) 3 (4–5) 3 (4–5)
alues are numbers (percentage of warts) unless stated otherwise.
a HPV3, 10, 28, 2, 27, 57 and 7 from the alpha genus, HPV4, 65, and 95 from the
amma genus, HPV1 and 63 from the mu genus, and HPV41 from the nu genus.
b Sum of percentages is /= 100 due to rounding off.n and plantar warts.
(78%). The combined contribution of the four most prevalent HPV
types (HPV 1, HPV 2, HPV 27 and HPV 57) was 82% in common
and 88% in plantar warts. For detailed information on the HPV type
prevalence and their relation with patient characteristics we refer
to a recent publication.27
4.2. HPV types and wart cure
Only the three most prevalent types (HPV 2, 27, and 57) for com-
mon  warts, and the four most prevalent types (HPV 2, 27, 57, and
1) for plantar warts had sufﬁcient numbers (>10) to compare treat-
ment arms (supplemental table). Since the CIs of cure rates of the
three highly prevalent HPV types 2, 27, and 57 from the alpha genus
species 4 overlapped for common as well as for plantar warts, we
combined cure rates for these HPV types. Thus, we identiﬁed three
subgroups of warts for which we could make reliable comparisons:
common warts with HPV 2/27/57 (n = 201), plantar warts with HPV
2/27/57 (n = 174), and plantar warts with HPV 1 (n = 85).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jcv.2013.02.021.
For common warts with HPV 2/27/57, the cure rate after a wait-
and-see policy was  2/70 (3%, 95% CI 1–10). Cryotherapy was the
most effective treatment for common warts with HPV 2/27/57:
30/44 (68%, 53–80) cured compared to 16/87 (18%, 12–28) cured
after salicylic acid (Fig. 2 and Table 2).
For plantar warts, the subgroup with HPV 1 had a favourable
natural course compared to those with HPV 2/27/57: 21/36 (58%,
95% CI 42–73) cured versus 4/58 (7%, 3–16) cured after a wait-and-
see policy (Table 2). For plantar warts with HPV 2/27/57, salicylic
acid [15/60, 25% (16–37) cured] was more effective compared to
wait-and-see, whereas cryotherapy [6/56, 11% (5–21) cured] was
not more effective than wait-and-see. For plantar warts with HPV
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Table 2
Natural course and treatment response of the three largest groupsa of warts based on type of wart (common or plantar) and wart-associated HPV type (n = 460).
Common warts Plantar warts
HPV 2/27/57
(n = 201)
HPV 2/27/57
(n = 174)
HPV 1
(n = 85)
Cure ratesb
Wait-and-see 2/70; 3 (1 to 10) 4/58; 7 (3 to 16) 21/36; 58 (42 to 73)
Cryotherapy 30/44; 68 (53 to 80) 6/56; 11 (5 to 21) 15/23; 65 (45 to 81)
Salicylic acid 16/87; 18 (12 to 28) 15/60; 25 (16 to 37) 24/26; 92 (76 to 98)
Relative risksc
Wait-and-see 1.0 1.0 1.0
Cryotherapy 23.9 (6.0 to 94.9) 1.6 (0.46 to 5.2) 1.1 (0.74 to 1.7)
Salicylic acid 6.4 (1.5 to 27.1) 3.6 (1.3 to 10.3) 1.6 (1.2 to 2.2)
Risk  differencesc
Wait-and-see 0 0 0
Cryotherapy 65 (51 to 80) 4 (−7 to 14) 7 (−18 to 32)
Salicylic acid 16 (7 to 25) 18 (5 to 31) 34 (15 to 53)
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b Cure rates are number of warts cured at 13 weeks/number of warts; percentage
c Relative risks (95% CIs) and risk differences (95% CIs) of active treatments comp
, salicylic acid [24/26, 92% (76–98) cured] was also more effec-
ive compared to wait-and-see, whereas cryotherapy [15/23, 65%
45–81) cured] was not more effective than wait-and-see (Fig. 2
nd Table 2).
In addition to the highly prevalent HPV types, plantar warts with
PV 4 from the gamma  genus showed sufﬁcient numbers (n = 17)
n the wait-and-see arm to reveal a speciﬁcally favourable natural
ourse: 16/17 (94%, 73–99) of warts cured (additional ﬁle 1). Per-
rotocol analysis did not reveal additional information. Cure rates
er treatment arm in warts negative for HPV DNA (n = 40) and warts
ith multiple HPV types (n = 118) were similar to our analysis of
ure rates of warts with single HPV types (n = 562).
. Discussion
.1. Main ﬁndings
HPV type inﬂuences the natural course and treatment response
or plantar warts. The probability of cure after a wait-and-see policy
as 8 times higher for HPV 1-associated plantar warts than for HPV
/27/57-associated plantar warts. Using the HSL-PCR/MPG assay in
ur primary care study population, 80% of plantar warts provided
 single HPV type of which 29% contained HPV 1. When treated,
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ig. 2. Cure rates per treatment group with 95% conﬁdence intervals stratiﬁed by
ype of warts (common or plantar) and warts-associated HPV type (n = 460).re cure rates.
 conﬁdence intervals [CIs]).
o wait-and-see policy as reference.
salicylic acid was more effective than cryotherapy for both HPV
subgroups of plantar warts. However, for common warts, cryother-
apy was  most effective. Since the majority of common warts were
associated with HPV 2/27/57, this study does not provide sufﬁcient
power to draw conclusions on the less prevalent HPV types.
5.2. Comparison with literature
This study conﬁrms that treatment response in common warts
is different from plantar warts,10 even when associated with the
same HPV type. Reasons for this difference are not fully understood
at present. Conceivably, skin location speciﬁc factors such as callus
are at play.
The short duration of warts with HPV 1 has been described ear-
lier, but has never been prospectively investigated or related to
treatment response.24 Only one other trial has investigated the
relation between cutaneous wart-associated HPV type and treat-
ment effect. Tomson et al. (2010) studied the effect of cryotherapy
on 54 common and plantar warts.26 They found that the response to
cryotherapy was unrelated to HPV type, but more likely the result
of the individual’s immune response to the virus. However, since
all warts were treated with cryotherapy, they could not investigate
differences between a wait-and-see policy or salicylic acid treat-
ment. Furthermore, the low number of warts prevented drawing
conclusions about HPV 1 associated warts.26
Compared to older HPV typing techniques, the HSL-PCR/MPG
assay is able to distinguish closely related HPV types 2, 27, and
57.20 The similar cure rates of these types are probably in line with
their high DNA homology in the alpha genus species 4,18 and corre-
spond with their similarity in relation to patient characteristics.27
Only 7% of all swabs were negative for HPV DNA in which unknown
HPV types could be involved. Alternatively, lesions (like callus)
could have been misdiagnosed as warts, or residual hyperkera-
totic lesions following HPV clearance could have been sampled.
Therefore we  could not use the swabs negative for HPV  DNA for
clinical prediction. The assay was  also capable of detecting mul-
tiple HPV types per wart. It is likely that only one HPV type is
responsible for the persistence of the wart; however, it is difﬁcult
to establish which one without using a technology such as laser
capture microdissection for which biopsies instead of wart swabs
are needed.27–29 Consequently, we  did not use swabs with multiple
HPV types for clinical prediction.5.3. Strengths and limitations
This study combined the broad spectrum HSL-PCR/MPG assay
and simple non-invasive swabs, which showed that HPV testing in
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ractice can be easy, quick, and reliable. The study was  embedded
n a high quality randomised trial in primary care.12 The two  most
requently used treatments in dermatology as well as primary care
ractice were included.9,11 However, the power of our analyses is
ower compared to the original trial, since we studied cure rates
n subgroups based on HPV types. Nevertheless, for the four most
revalent HPV types, numbers of warts per HPV type per treatment
rm were high enough to make reliable comparisons. Although the
riginal trial randomised the patients, we determined HPV type in
eparate warts. Because more than half of all patients had multiple
arts, the number of warts in the cryotherapy arm was less than
he numbers in the other two arms due to chance.
This study allows us to conclude that the HPV type inﬂuences
he natural course and treatment response, which is different from
rawing conclusions about causal relations. One could argue that
ome wart characteristics are confounders, or are in fact in the
ausal pathway between HPV type and cure.30 For example, HPV 1 is
ssociated with a low number of warts per patient. HPV 1 often has
ndophytic growth patterns and high viral loads. It is hypothesised
hat this could trigger the immune system and limit the spread of
arts, both of which could contribute to the favourable cure rates.31
ncreasing numbers of warts per patient may  reﬂect poor immune
esponses to the HPV type inducing these warts. However, we  did
ot study the immune response in this cohort of patients. Thus,
or our research question related to prognosis only, we  chose to
resent crude cure rates without adjustment.
.4. Implications
This study reveals that HPV type may  inﬂuence the choice of
reatment for plantar warts. In daily practice, detection of HPV 1
n plantar warts implies a favourable natural course and may  lead
o advise the patient to wait-and-see. Detection of HPV 2/27/57 in
lantar warts implies a persistent wart, which in most cases is resis-
ant to treatment. However, when treatment is preferred, salicylic
cid can be considered. For common warts, HPV typing does not yet
ontribute to the choice of treatment, because cryotherapy is effec-
ive in the majority of HPV2/27/57-associated warts. Future studies
hould reveal whether less prevalent HPV types causing common
arts will be associated with lower cure rates. With our ﬁndings,
e have opened a new direction to optimise wart treatment.
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